TRANSLATIONAL LUNG CANCER RESEARCH : Impact Factor & More
eISSN: 2226-4477pISSN: 2218-6751
Share this on:
Key Metrics
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on TRANSLATIONAL LUNG CANCER RESEARCH
TRANSLATIONAL LUNG CANCER RESEARCH Journal Specifications
| Overview | |
| Publisher | AME PUBLISHING COMPANY |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in TRANSLATIONAL LUNG CANCER RESEARCH ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in TRANSLATIONAL LUNG CANCER RESEARCH
Mid-term efficacy and safety of transbronchial cryoablation for stage IA peripheral lung cancer: a retrospective analysis
- 1 Apr 2026
- Translational Lung Cancer Research
Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB–IIIA non-small cell lung cancer
- 1 Apr 2026
- Translational Lung Cancer Research
Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report
- 1 Apr 2026
- Translational Lung Cancer Research
Targeted therapy for stage IA non-small cell lung cancer with EGFR mutations: a scoping review
- 1 Apr 2026
- Translational Lung Cancer Research
Pulmonary ground glass opacity tumor: a curable subtype of lung cancer when treated within the “surgical curative time window”
- 1 Apr 2026
- Translational Lung Cancer Research
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling
- 1 Apr 2026
- Translational Lung Cancer Research
Mid-term efficacy and safety of transbronchial cryoablation for stage IA peripheral lung cancer: a retrospective analysis
- 1 Apr 2026
- Translational Lung Cancer Research
Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB–IIIA non-small cell lung cancer
- 1 Apr 2026
- Translational Lung Cancer Research
Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report
- 1 Apr 2026
- Translational Lung Cancer Research
Targeted therapy for stage IA non-small cell lung cancer with EGFR mutations: a scoping review
- 1 Apr 2026
- Translational Lung Cancer Research
Pulmonary ground glass opacity tumor: a curable subtype of lung cancer when treated within the “surgical curative time window”
- 1 Apr 2026
- Translational Lung Cancer Research
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling
- 1 Apr 2026
- Translational Lung Cancer Research
FAQs on TRANSLATIONAL LUNG CANCER RESEARCH
How long has TRANSLATIONAL LUNG CANCER RESEARCH been actively publishing? 
What is the publishing frequency of TRANSLATIONAL LUNG CANCER RESEARCH?
How many articles did TRANSLATIONAL LUNG CANCER RESEARCH publish last year?
What is the eISSN & pISSN for TRANSLATIONAL LUNG CANCER RESEARCH?
Who is the publisher of TRANSLATIONAL LUNG CANCER RESEARCH?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations